Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Cynata Therapeutics is a pre-revenue Australian clinical-stage biotechnology company developing Cymerus, a proprietary mesenchymal stem cell (MSC) platform technology derived from induced pluripotent stem cells (iPSCs). The company is advancing multiple clinical programs targeting inflammatory conditions including graft-versus-host disease (GvHD), osteoarthritis, and respiratory conditions, with partnerships in Japan (Fujifilm) and other regions providing non-dilutive funding. The stock trades on clinical trial readouts, partnership announcements, and capital raising events.
Cynata operates a platform-based model where its Cymerus iPSC-derived MSC technology enables scalable, off-the-shelf allogeneic cell therapy production without donor variability. The company monetizes through: (1) regional licensing deals providing upfront payments, milestones, and royalties (Fujifilm partnership for Japan covers development costs for specific indications), (2) R&D tax incentives reducing net cash burn by 20-30%, and (3) eventual product commercialization if clinical trials succeed. Competitive advantage lies in manufacturing scalability versus donor-derived MSCs and potential cost-of-goods advantages enabling broader market access. Current strategy focuses on advancing lead programs (GvHD, osteoarthritis) to Phase 2/3 data to attract acquisition interest or larger partnerships.
Clinical trial data readouts for lead programs (Phase 2 GvHD efficacy data, osteoarthritis Phase 1/2 results) - positive data can drive 30-100% moves
Partnership announcements or expansions (additional indications with Fujifilm, new regional licensing deals) providing validation and non-dilutive funding
Capital raising announcements (equity placements, institutional rounds) - typically 10-25% dilutive, causing 15-30% stock declines
Regulatory milestones including IND approvals for new indications or Fast Track/Orphan Drug designations from FDA/EMA
Manufacturing scale-up announcements demonstrating commercial viability and cost-of-goods improvements
Clinical trial failure risk is existential - Phase 2/3 trials have 30-40% success rates in cell therapy, and any efficacy failure would eliminate near-term commercialization pathway and require pivot or wind-down
Regulatory pathway uncertainty for allogeneic cell therapies with evolving FDA/EMA guidance on manufacturing controls, potency assays, and long-term safety monitoring requirements
Reimbursement risk as payers globally scrutinize high-cost cell therapies, potentially limiting addressable market even with regulatory approval
Established MSC competitors including Mesoblast (donor-derived MSCs with more advanced clinical programs) and Athersys competing for same indications with different technology platforms
Large pharma in-house cell therapy programs (Bristol Myers Squibb, Novartis) with significantly greater resources and manufacturing infrastructure
Technology risk that iPSC-derived MSCs may not demonstrate superiority over donor-derived cells in clinical efficacy, eliminating theoretical competitive advantage
Capital raise dependency with current cash runway estimated at 12-18 months based on AUD 8-12M annual burn, requiring periodic dilutive equity raises
Small market capitalization (AUD 100M) limits institutional ownership and creates liquidity risk with wide bid-ask spreads
Foreign exchange exposure as Australian-listed company with potential future revenues in USD/JPY, though currently minimal operational impact
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, partnership activity and M&A appetite from larger pharma acquirers increases during economic expansions when corporate balance sheets are strong and risk appetite is elevated. Funding environment for biotech IPOs and follow-on offerings tightens significantly during recessions, potentially forcing dilutive capital raises.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (product revenues not expected until 2028+). Higher rates also reduce speculative capital flowing into pre-revenue biotechs as investors rotate to safer yield-generating assets. Cynata's zero debt means no direct financing cost impact, but capital raising becomes more difficult and dilutive in high-rate environments. The 10-year Treasury yield serves as the risk-free rate baseline for DCF models used by institutional investors.
Minimal - Company has no debt and operates on equity capital. Credit market conditions affect larger pharma partners' ability to fund licensing deals and acquisitions, indirectly impacting partnership opportunities.
growth/speculative - Attracts high-risk-tolerance investors seeking asymmetric returns from clinical trial success or acquisition. Typical holders include retail biotech enthusiasts, specialized healthcare hedge funds, and Australian small-cap growth funds. Not suitable for income or value investors given pre-revenue status and binary clinical outcomes. Recent 55-95% returns over 3-12 months indicate momentum trader participation.
high - Clinical-stage biotechs exhibit 60-100% annualized volatility driven by binary clinical events. Small market cap and limited liquidity amplify price swings. Stock can move 20-50% on single news items (trial data, partnership announcements, capital raises). Beta to broader market is low but idiosyncratic risk is extreme.
